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Abstract 
Cardiomyocyte hypertrophy is an integral component of pathological cardiac 
remodelling in response to mechanical and chemical stresses in settings such as 
chronic hypertension or myocardial infarction. For hypertrophy to ensue, the 
pertinent mechanical and chemical signals need to be transmitted from 
membrane sensors (such as receptors for neurohormonal mediators) to the 
cardiomyocyte nucleus, leading to altered transcription of the genes that 
regulate cell growth. In recent years, nuclear histone deacetylases (HDACs) have 
attracted considerable attention as signal-responsive, distal regulators of the 
transcriptional reprogramming that in turn precipitates cardiomyocyte 
hypertrophy, with particular focus on the role of members of the class IIa family, 
such as HDAC4 and HDAC5. These histone deacetylase isoforms appear to 
repress cardiomyocyte hypertrophy through mechanisms that involve protein 
interactions in the cardiomyocyte nucleus, particularly with pro-hypertrophic 
transcription factors, rather than via histone deacetylation. In contrast, evidence 
indicates that class I HDACs promote cardiomyocyte hypertrophy through 
mechanisms that are dependent on their enzymatic activity and thus sensitive to 
pharmacological HDAC inhibitors. Although considerable progress has been 
made in understanding the roles of post-translational modifications (PTMs) such 
as phosphorylation, oxidation and proteolytic cleavage in regulating class IIa 
HDAC localization and function, more work is required to explore the 
contributions of other PTMs, such as ubiquitination and sumoylation, as well as 
potential cross-regulatory interactions between distinct PTMs and between class 
IIa and class I HDAC isoforms. 
 
Introduction 
Histone deacetylases (HDACs) are an ancient family of enzymes that catalyse the 
removal of acetyl groups from the ε-amino group of specific acetyl lysine 
residues within their protein substrates. Deacetylation of histones in 
nucleosomes induces chromatin condensation, which represses transcription by 
preventing binding of transcription factors and other components of the 
transcriptional machinery to gene promoter and enhancer regions. Conversely, 
 3
acetylation of histones by histone acetyltransferases (HATs) induces chromatin 
relaxation, resulting in increased gene transcription. Thus, HDACs and HATs 
serve as important and opposing epigenetic regulators of gene expression. 
Of the four classes of non-sirtuin HDACs (I, IIa, IIb and IV; see Figure 1), class I 
and IIa are the best studied with regards to cardiac biology and pathology. 
Genetically modified mouse models and the use of pharmacological HDAC 
inhibitors in experimental models of cardiovascular disease have revealed 
important roles for both class I and IIa HDACs in the regulation of cardiac 
structure and function (see Tables 1 and 2). Administration of small molecule 
HDAC inhibitors, such as trichostatin A (TSA), SAHA and valproic acid, blocks 
pathological cardiac changes in a range of experimental settings (see Table 1). 
For example, administration of TSA two weeks after the induction of pressure 
overload reversed cardiac hypertrophy in mice (Kee et al., 2006), and 
administration of SAHA at reperfusion reduced infarct size and improved cardiac 
function in a rabbit model of ischemia/reperfusion injury (Xie et al., 2014). The 
pharmacophore of most HDAC inhibitors developed to date contains a zinc-
binding group that chelates the zinc ion required for catalytic activity (Bertrand, 
2010; McKinsey, 2011). As the principal mechanism by which class IIa HDACs 
regulate cardiomyocyte hypertrophy is not dependent on their catalytic activity 
(Zhang et al., 2002a), and class IIa HDACs are relatively insensitive to HDAC 
inhibitors (Lahm et al., 2007; Bradner et al., 2010), the efficacy of HDAC 
inhibitors in attenuating pathological cardiac remodelling in animal models is 
likely a consequence of their inhibition of class I HDAC isoforms. Although we are 
not aware of conclusive clinical evidence regarding the therapeutic potential of 
HDAC inhibitors in the context of heart failure, in patients with epilepsy 
treatment with valproic acid appears to be associated with a reduced risk of 
myocardial infarction (Olesen et al., 2011). 
Class IIa HDACs are endogenous inhibitors of cardiomyocyte hypertrophy and 
are therefore referred to as “anti-hypertrophic”. Class IIa HDACs suppress 
cardiomyocyte hypertrophy when localised in the nucleus by repressing the 
activity of pro-hypertrophic transcription factors, such as members of the 
myocyte enhancer factor-2 (MEF2) family (Lu et al., 2000; Zhang et al., 2002a), 
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and by recruiting epigenetic regulators such as class I HDACs and histone 
methyltransferases to DNA promoter regions (Fischle et al., 2002; Zhang et al., 
2002b; Hohl et al., 2013). Nuclear export of class IIa HDACs permits the 
induction of hypertrophic genes by alleviating their repressive interactions with 
transcription factors and allowing the recruitment of HATs and histone 
demethylases. The relative importance of and interplay between class I and class 
IIa HDAC isoforms in regulating cardiomyocyte hypertrophy and other 
components of pathological cardiac remodelling such as fibrosis are the subject 
of intense research. The recent discovery that cardiac class IIa HDACs may 
regulate the acetylation status and activity of class I HDACs (Eom et al., 2014) 
reveals a new layer of complexity that warrants further investigation as part of 
this effort.  
HDACs are subject to various post-translational modifications, including 
phosphorylation, proteolytic cleavage, oxidation, ubiquitination and 
sumoylation. This review will focus on the roles and regulation of class IIa 
HDACs in the context of cardiomyocyte hypertrophy and cardiac remodelling, 
with emphasis on post-translational modifications that alter the function of 
individual members of this class. For broader reviews covering other HDAC 
classes and their potential as targets for cardiac pharmacotherapy, the reader is 
referred to recent review articles from the laboratories of two leading 
investigators in the field, Timothy McKinsey (McKinsey, 2012) and Joseph Hill 
(Xie & Hill, 2013). 
Class IIa HDACs 
The HDAC superfamily can be divided into four classes, based on sequence 
similarity and functional domains (see Figure 1). Class I and II HDACs are 
conserved amongst prokaryotes and eukaryotes, while class IV HDACs are 
present in all organisms except fungi (Gregoretti et al., 2004). Class III HDACs are 
more commonly known as sirtuins and constitute an unrelated class of NAD-
dependent deacetylases (Landry et al., 2000).  
The class II HDACs can be further divided into two subclasses. Class IIa includes 
HDAC4, HDAC5, HDAC7, HDAC9 and a truncated splice variant of HDAC9 known 
as MEF2-interacting transcriptional repressor (MITR) or HDAC-related protein 
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(HDRP). Class IIb includes HDAC6 and HDAC10. Unlike class I HDACs, which are 
widely expressed (Yang et al., 1997; Hu et al., 2000), class IIa HDAC expression is 
restricted to a subset of tissues and cell types. In humans and mice, expression of 
HDAC4, HDAC5 and HDAC9 is highest in heart, brain and skeletal muscle 
(Grozinger et al., 1999; Zhou et al., 2001), whereas HDAC7 expression is 
restricted to endothelial cells within the heart, lung and skeletal muscle (Kao et 
al., 2000; Chang et al., 2006). Expression of MITR/HDRP is highest in heart and 
brain (Zhou et al., 2000; Zhang et al., 2001). Serial analysis of gene expression 
(SAGE) has identified HDAC5 as the most abundant HDAC transcript in the adult 
human heart (de Ruijter et al., 2003). 
Structure and function of class IIa HDACs 
With the exception of MITR/HDRP, which lacks a deacetylase domain, class IIa 
HDACs consist of a C-terminal deacetylase domain and an extensive N-terminal 
regulatory domain. Class IIa HDACs have very low deacetylase activity towards 
native acetyl lysine residues, despite being capable of deacetylating the synthetic 
substrate trifluoro acetyl lysine in vitro (Bradner et al., 2010). This is due to the 
replacement of a conserved tyrosine residue with a histidine residue within the 
deacetylase domain of class IIa HDACs, which markedly impairs catalytic activity 
(Lahm et al., 2007). It has been proposed that the deacetylase domain of class IIa 
HDACs functions as a binding domain, as class IIa HDACs bind acetyl lysine 
substrates with comparable affinity to class I and IIb HDACs, despite being 
unable to deacetylate these substrates (Bradner et al., 2010). It has also been 
suggested that deacetylase activity associated with class IIa HDACs purified from 
cells or tissue most likely arises from the presence of HDAC3 in class IIa HDAC 
repressor complexes (Fischle et al., 2002). 
As illustrated in Figure 2, the regulatory domain of class IIa HDACs contains a 
MEF2 binding motif, a nuclear localisation signal (NLS), and several conserved 
serine residues that act as docking sites for 14-3-3 proteins when 
phosphorylated. The best characterised HDAC kinases in the context of cardiac 
biology and pathology are Ca
2+
/calmodulin-dependent protein kinase II 
(CaMKII) and protein kinase D (PKD). However, in various cell types and in vitro 
settings, class IIa HDACs appear to be substrates also for protein kinase A (PKA), 
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G protein-coupled receptor kinase-5, microtubule affinity-regulating kinases, 
salt-inducible kinases and AMP-dependent protein kinases (Chang et al., 2005; 
Dequiedt et al., 2006; Berdeaux et al., 2007; McGee et al., 2008; Ha et al., 2010; 
Zhang et al., 2011; Walkinshaw et al., 2013a). Association with 14-3-3 proteins 
masks the NLS and sequesters HDACs in the cytoplasm, following unveiling of a 
C-terminal nuclear export sequence and transport out of the nucleus by the 
nuclear export receptor CRM1 (Grozinger & Schreiber, 2000; McKinsey et al., 
2001; Harrison et al., 2004). Nucleo-cytoplasmic shuttling appears to be the 
primary mechanism regulating class IIa HDAC function, as exclusion from the 
nucleus prevents the repressive interaction of HDACs with transcription factors, 
resulting in increased transcription of target genes (Miska et al., 1999; Lu et al., 
2000; Harrison et al., 2004). In the case of MEF2, nuclear export of class IIa 
HDACs permits interaction with the HAT, E1 binding protein p300 (p300), which 
promotes pro-hypertrophic gene transcription via its effects on histone 
acetylation and the formation of enhanceosomes (Wei et al., 2008; He et al., 
2011). p300 is also capable of directly acetylating MEF2, which enhances DNA 
binding and transcriptional activity (Ma et al., 2005).  
Regulation of cardiac remodelling by class IIa HDACs 
The majority of the evidence implicating class IIa HDACs in the regulation of 
cardiomyocyte hypertrophy and cardiac remodelling comes from genetically 
modified mouse models (see Table 2), most of which have been generated in the 
laboratory of Eric Olson, and in vitro studies in primary and immortalised cell 
lines. Heterologously expressed HDAC4 and HDAC5 are predominantly nuclear, 
but accumulate in the cytoplasm upon exposure to pro-hypertrophic stimuli, 
such as the α
1
-adrenergic receptor agonist phenylephrine (PE) and endothelin-1 
(ET-1) (Harrison et al., 2004; Vega et al., 2004a; Ago et al., 2008; Peng et al., 
2009; Backs et al., 2011; Haworth et al., 2012; Chang et al., 2013). Blocking class 
IIa HDAC nuclear export with CRM1 inhibitors, such as leptomycin B or its 
derivatives, or by mutation of the HDAC 14-3-3 docking sites to non-
phosphorylatable alanine residues, prevents cardiomyocyte hypertrophy 
(Harrison et al., 2004; Vega et al., 2004a; Monovich et al., 2009), providing strong 
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evidence that such nuclear export is required for the induction of the 
hypertrophic response.  
Mice globally deficient in either HDAC5 or HDAC9 were viable, but developed 
cardiac hypertrophy even in the absence of an imposed stress by approximately 
8 months of age (Zhang et al., 2002a; Chang et al., 2004). In contrast, compound 
deletion of both Hdac5 and Hdac9 resulted in embryonic lethality due to 
haemorrhage and ventricular defects (Chang et al., 2004). The small percentage 
of double-knockout mice that survived to adulthood were severely growth 
retarded and displayed significant cardiac hypertrophy, demonstrating that 
HDAC5 and HDAC9 have important functions in embryonic and postnatal cardiac 
development. 
Mice with individual deletion of Hdac5 or Hdac9 displayed an exaggerated 
hypertrophic response to pressure overload, induced by constriction of the 
thoracic aorta, suggesting that these HDAC isoforms function to limit cardiac 
enlargement following haemodynamic overload (Zhang et al., 2002a; Chang et 
al., 2004). Both genotypes also displayed profound hypertrophic growth 
compared with wild-type littermates when crossed with transgenic mice 
expressing activated calcineurin, an important transducer of pro-hypertrophic 
signalling (Molkentin et al., 1998). The findings that HDAC5 and HDAC9 
knockout mice respond similarly to hypertrophic stimuli, and that HDAC5/9 
double-knockout mice are embryonically lethal, suggest that these isoforms are 
activated by similar signalling pathways and have overlapping functions. 
Functional redundancy of class IIa HDACs has been observed also in the context 
of fibre type switching in skeletal muscle; deletion of individual class IIa HDAC 
isoforms had no effect on the proportion of type I and type II fibres in mouse 
soleus muscle, whereas heterozygous or homozygous deletion of multiple 
isoforms (Hdac4/5, Hdac5/9 or Hdac4/5/9) increased the percentage of type I 
fibres (Potthoff et al., 2007).  
Mice with global deletion of Hdac4 die prior to weaning due to severe growth 
retardation resulting from the premature ossification of developing bones (Vega 
et al., 2004b). Although no obvious cardiac abnormalities were observed in these 
mice, it was impossible to examine the effects of Hdac4 deletion on stress-
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induced cardiac hypertrophy as the mice died prior to adulthood. Mice with 
cardiomyocyte-specific deletion of Hdac4 have since been generated (Hohl et al., 
2013), but the effects of hypertrophic stress on their cardiac phenotype have not 
been described in detail to date. In their recent collaborative study, the 
laboratories of Johannes Backs and Christoph Maack have used these mice, as 
well as tissue samples from failing and non-failing human myocardium, to 
investigate the epigenetic regulation of Nppa and Nppb, foetal genes encoding 
the atrial and B-type natriuretic peptides ANP and BNP, which are re-expressed 
during cardiac hypertrophy and heart failure (Hohl et al., 2013). Their findings 
support the hypothesis that class IIa HDACs repress MEF2-dependent gene 
transcription by recruiting the methyltransferase SUV39H1 and the adaptor 
protein heterochromatin protein 1 (HP1) to promoter regions, as part of a 
corepressor complex (Zhang et al., 2002b). Nuclear export of HDAC4 in response 
to elevated cardiac load may increase expression of ANP and BNP, not via effects 
on histone acetylation but via histone demethylation by JMJC domain-containing 
demethylases, following dissociation of HP1 and SUV39H1 (Hohl et al., 2013). 
Whether similar mechanisms operate in HDAC4-mediated regulation of other 
hypertrophic genes, or in the regulation of ANP and BNP expression by other 
class IIa HDACs, has not been reported. 
Mice with global deletion of Hdac7 die during embryogenesis due to 
cardiovascular defects (Chang et al., 2006). Conditional deletion of Hdac7 in 
endothelial cells phenocopied global deletion, whereas mice with conditional 
deletion of Hdac7 in cardiomyocytes were viable (Chang et al., 2006). Thus, any 
effect of HDAC7 on cardiac remodelling is likely to arise predominantly from its 
function in endothelial cells. In this context, PKD-mediated phosphorylation of 
HDAC7 following VEGF stimulation of endothelial cells led to nuclear export of 
HDAC7, increased MEF2 activity and enhanced angiogenesis in an ex vivo assay 
(Ha et al., 2008a). Nuclear export of HDAC5 was shown to have a similar pro-
angiogenic effect (Ha et al., 2008b). As insufficient angiogenesis is a critical 
determinant of the transition from compensatory cardiac hypertrophy to 
decompensated heart failure (Shiojima et al., 2005), it is likely that class IIa 
HDACs regulate pathological cardiac remodelling via their functions in multiple 
cell types, including endothelial cells, and not just in cardiomyocytes. It follows 
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from this that any new therapies targeted at class IIa HDAC nucleocytoplasmic 
shuttling may need to exhibit cell specificity, in order to limit cardiomyocyte 
hypertrophy but not compromise angiogenesis during cardiac remodelling. 
Post-translational modifications regulating class IIa HDAC function 
Phosphorylation 
HDAC5 contains at least 17 phospho-acceptor residues that are conserved across 
species, which suggests that phosphorylation is a fundamental post-translational 
modification regulating HDAC5 folding and function (Greco et al., 2011). The best 
characterised HDAC5 phosphorylation sites are Ser259 and Ser498, which flank 
the NLS, and Ser279, which lies within the NLS. Homologous sites are present in 
HDAC4 (see Figure 2) and HDAC9. As mentioned previously, phosphorylation of 
Ser259 and Ser498 in HDAC5 by CaMKII or PKD induces nuclear export 
(McKinsey et al., 2000a; McKinsey et al., 2000b; Vega et al., 2004a; Backs et al., 
2006; Backs et al., 2008). In contrast, phosphorylation of Ser279 by protein 
kinase A (PKA) has been proposed to promote nuclear retention (Ha et al., 2010; 
Chang et al., 2013; Walkinshaw et al., 2013b), possibly by inducing a 
conformational change that prevents binding of 14-3-3 proteins at 
phosphorylated Ser259 and Ser498 (Ha et al., 2010).  
Expression and activity of CaMKIIδ and PKD are elevated in failing human 
myocardium (Bossuyt et al., 2008), and both kinases contribute to pathological 
remodelling in rodents (Fielitz et al., 2008; Backs et al., 2009). HDAC4 contains a 
unique CaMKII docking site that promotes interaction with activated CaMKII and 
subsequent phosphorylation of Ser467 and Ser632 (Backs et al., 2006). HDAC5 
lacks a CaMKII docking site, but can be phosphorylated by CaMKII when bound 
to HDAC4 via its coiled-coil domain (Backs et al., 2008). Nuclear CaMKIIδ 
phosphorylates HDAC5 following InsP
3
-induced Ca
2+
 release from the nuclear 
envelope (Wu et al., 2006), while cytosolic CaMKIIδ could maintain HDACs in a 
phosphorylated state once exported to the cytoplasm (Backs et al., 2006). PKD1, 
which is predominantly cytosolic under basal conditions, associates with the 
sarcolemma upon PE stimulation, then rapidly translocates to the nucleus where 
it phosphorylates HDAC5 (Bossuyt et al., 2011).  
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Intriguingly, recent evidence suggests that nuclear export of HDAC5 may occur 
independently of increases in Ser259 and Ser498 phosphorylation. Stimulation 
with the β-adrenergic receptor (β-AR) agonist isoprenaline induced nuclear 
export of HDAC5 in adult rat ventricular myocytes, but this was accompanied by 
reduced phosphorylation of the relevant 14-3-3 docking sites (Haworth et al., 
2012). The mechanism(s) responsible for reduced HDAC5 phosphorylation in 
this experimental setting is not yet known. Of interest, all three subunits of the 
heterotrimeric protein phosphatase 2A (PP2A) holoenzyme co-
immunoprecipitate with HDAC5 when stably expressed in HEK293 cells (Greco 
et al., 2011) and PP2A has been found to dephosphorylate HDAC4 in vitro 
(Paroni et al., 2008). Whether PP2A-mediated dephosphorylation contributes to 
reduced HDAC5 phosphorylation at Ser259 and Ser498 in response to β-
adrenergic stimulation in cardiac myocytes, and the role of any such 
dephosphorylation in regulating the nuclear localisation of HDAC5, require 
further investigation.  
The phosphorylation status of Ser279 appears to be a key determinant of HDAC5 
localisation, as mutation to a phosphomimetic aspartic acid residue promoted 
nuclear accumulation and rendered HDAC5 resistant to nuclear export induced 
by PE or ET1 stimulation in neonatal rat and adult rabbit cardiac myocytes (Ha 
et al., 2010; Chang et al., 2013). Furthermore, mutation of Ser279 to alanine 
promoted cytoplasmic accumulation in U2OS cells, consistent with the 
hypothesis that phosphorylation of Ser279 promotes nuclear retention (Greco et 
al., 2011). However, no change in basal distribution was observed with a 
Ser279Ala HDAC5 mutant in adult rabbit cardiac myocytes (Chang et al., 2013). 
In the same study, it was proposed that phosphorylation of Ser279 by β-AR-
mediated activation of PKA promotes nuclear import/retention of HDAC5, as 
isoprenaline and forskolin, an activator of adenylyl cyclase, induced nuclear 
import of wild-type HDAC5, but had no effect on the localisation of the Ser279Ala 
mutant (Chang et al., 2013). As noted above, the β-AR agonist isoprenaline has 
been reported to induce HDAC5 nuclear export and increased MEF2 activity in 
adult rat ventricular myocytes (Haworth et al., 2012). Thus the regulation of 
HDAC5 localisation and function by β-AR stimulation and the roles of 
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phosphorylation/dephosphorylation at regulatory serine residues appear to also 
warrant additional investigation.  
With regards to adrenergic regulation of class IIa HDACs, very recent evidence 
suggests that increased HDAC4/5 phosphorylation and consequent MEF2 
activation following endothelin-1 stimulation may occur primarily through 
stimulation of α
1
- and β
1
-ARs on cardiomyocytes, following activation of 
presynaptic ET
A
 receptors and subsequent inhibition of noradrenaline reuptake 
into sympathetic nerve terminals (Lehmann et al., 2014). This observation 
suggests that there is significant crosstalk between different neurohormonal 
stimuli in the regulation of class IIa HDACs, not only downstream of pertinent 
GPCRs within cardiomyocytes but also through neuronal presynaptic receptors. 
Proteolytic cleavage 
An additional mechanism by which PKA may regulate the function of HDAC4 has 
been described in a study by the laboratories of Backs and Olson (Backs et al., 
2011). HDAC4 contains a cleavage site (Tyr201), which is not present in other 
class IIa HDACs (see Figure 2), and activation of PKA leads to HDAC4 cleavage at 
this site by an as yet unidentified serine protease, resulting in the production of 
an N-terminal fragment (HDAC4-NT) that accumulates in the nucleus where it 
represses MEF2 activity. HDAC4-NT was detected in hearts from wild-type mice 
following isoprenaline administration over a four-hour period, but not in hearts 
from mice lacking the catalytic α subunit of PKA, confirming that PKA-dependent 
generation of HDAC4-NT can occur in vivo downstream of β-AR stimulation. It 
has been suggested that this mechanism may allow cardiomyocytes to exhibit 
differential hypertrophic responses to acute adrenergic activation in 
physiological stress situations and to sustained neurohormonal stimulation 
during prolonged periods of cardiac stress in disease (Backs et al., 2011). 
Accordingly, during acute β-AR stimulation, PKA-mediated generation of HDAC4-
NT would reign in MEF2 activity, attenuating hypertrophic gene transcription. In 
settings of sustained neurohormonal stimulation, involving also other mediators 
such as ET-1, angiotensin II and reactive oxygen species (see Oxidation section 
below), CaMKII- and PKD-mediated, phosphorylation-dependent as well as 
phosphorylation-independent mechanisms of class IIa HDAC nuclear export 
 12
would predominate, leading to MEF2 activation and pathological cardiac 
remodelling. In this context, selective stimulation of β-ARs is sufficient to induce 
cardiomyocyte hypertrophy and cardiac remodelling (Osadchii, 2007) and β-AR 
antagonists are clinically proven therapies for chronic heart failure (Bristow, 
2011). It seems likely, therefore, that any HDAC4-NT-mediated anti-
hypertrophic consequences of β-AR stimulation are indeed short lasting, and/or 
that mechanisms that are independent of class IIa HDACs make a predominant 
contribution to cardiomyocyte hypertrophy and cardiac remodelling during 
chronic β-AR stimulation.  
There is evidence that HDAC4 can be cleaved also by caspase-2 and caspase-3 at 
Asp289 (Paroni et al., 2004). The resulting N-terminal fragment augments 
apoptosis via the repression of serum response factor (SRF) and Runx2 (Liu et 
al., 2004; Paroni et al., 2004; Paroni et al., 2007; Backs et al., 2011). Whether this 
proteolytic cleavage event occurs in the heart and has a functional role during 
cardiac stress responses has not been explored. 
Oxidation 
Junichi Sadoshima and colleagues have identified oxidation as a novel 
phosphorylation-independent post-translational modification regulating 
subcellular localisation of HDAC4 in cardiomyocytes (Ago et al., 2008) and 
suggested that nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4) 
plays an important role in generating the relevant oxidative signal (Matsushima 
et al., 2013). Although the precise mechanism of oxidation-induced nuclear 
export is unknown, it has been proposed that formation of an intra-molecular 
disulphide bond between two conserved cysteine residues (Cys667 and Cys669 
in HDAC4; see Figure 2) disrupts zinc coordination, leading to a conformational 
change that exposes the nuclear export signal to CRM1 (Ago et al., 2008). HDAC5 
appears to be regulated in a similar manner, as isoprenaline-induced nuclear 
export of HDAC5 was blocked by overexpression of the disulphide 
oxidoreductase protein thioredoxin-1 or in the presence of the antioxidant N-
acetylcysteine (Haworth et al., 2012).  
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Ubiquitination 
Ubiquitination plays a critical role in cell homeostasis, regulating protein 
turnover by targeting proteins for degradation by the proteasome. Reversible 
ubiquitination of protein substrates also serves an important role in signal 
transduction and has been shown to modulate gene expression in several cardiac 
disease settings (Portbury et al., 2012). Although HDAC ubiquitination has not 
been studied in the heart, a study in skeletal muscle suggests that ubiquitination 
is an important post-translational modification that regulates class IIa HDAC 
function (Potthoff et al., 2007). In this study, ubiquitination and subsequent 
degradation of class IIa HDACs promoted the expression of slow twitch fibre-
specific genes by alleviating their repressive interaction with MEF2 (Potthoff et 
al., 2007). Proteasomal inhibition in mice resulted in increased HDAC4 and 
HDAC5 expression and reduced MEF2 activity in various skeletal muscles, while 
Cre-mediated deletion of multiple class IIa HDACs resulted in a switch from fast- 
to slow-twitch fibres, demonstrating that ubiquitination is an important post-
translational mechanism that maintains appropriate levels of HDAC expression. 
Whether ubiquitination of class IIa HDACs is important in cardiac biology is yet 
to be explored, but this seems likely.  
Sumoylation 
Sumoylation, the covalent attachment of small ubiquitin-like modifier (SUMO) 
proteins to target proteins, is emerging as an important post-translational 
mechanism regulating cardiovascular homeostasis (Kho et al., 2011; Wang et al., 
2011). HDAC4 is sumoylated in HeLa cells, possibly as it enters the nucleus 
through the nuclear pore complex (Kirsh et al., 2002). Interestingly, interaction 
with HDAC4 or HDAC5 potentiates the sumoylation of MEF2, which renders 
MEF2 transcriptionally inactive, and ablation of the SUMO conjugation site in 
HDAC4 dampens the repressive effect of HDAC4 on MEF2-dependent gene 
transcription (Gregoire & Yang, 2005; Zhao et al., 2005). Whether altered 
sumoylation of class IIa HDACs plays a role in the pathogenesis of cardiovascular 
disease has not been investigated. 
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Summary 
Figure 2 summarises the current state of knowledge regarding the opposing 
roles of class IIa and class I HDAC isoforms in regulating pathological cardiac 
remodelling and outlines the multiple PTMs that have already been shown to 
regulate class IIa HDAC function, as well as those that warrant further 
investigation, in this context.  Over the past decade or more, substantial evidence 
has accumulated that class IIa HDAC isoforms such as HDAC4 and HDAC5 are 
important regulators of cardiomyocyte hypertrophy and pathological cardiac 
remodelling, principally through their repressive effects on MEF2 transcription 
factor activity when enriched in the nucleus. Importantly, the subcellular 
localisation, integrity and MEF2 interaction of class IIa HDAC isoforms appear to 
be regulated by multiple post-translational mechanisms such as 
phosphorylation, oxidation and proteolytic cleavage, and potentially 
sumoylation, ubiquitination and proteasomal degradation. Greater 
understanding of such mechanisms, and potential cross-regulatory interactions 
between them, may allow the development of new therapeutic approaches 
towards harnessing the “anti-hypertrophic” actions of class IIa HDAC isoforms 
under conditions of chronic mechanical and neurohormonal stress and thereby 
attenuating pathological cardiac remodelling. This is particularly relevant given 
recent reports that class IIa HDACs can additionally regulate the expression and 
activity of “pro-hypertrophic’ class I HDACs (Spallotta et al., 2013; Eom et al., 
2014). A greater understanding of the interplay between different HDAC classes 
at different stages of disease, as well as the interplay between HDACs and other 
epigenetic regulators, such as bromodomain and extra-terminal acetyl-lysine 
reader proteins (Anand et al., 2013; Spiltoir et al., 2013), is likely to aid the 
development of new targeted therapies for the prevention or reversal of 
pathological cardiac remodelling and heart failure.  
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Figure legends 
Figure 1: A) The histone deacetylase (HDAC) family is comprised of four classes. 
Class II HDACs are further categorised into subclasses. Class I and class IIa HDAC 
isoforms are the best characterised with regards to cardiomyocyte hypertrophy 
and cardiac remodelling. This review focuses primarily on the Class IIa subclass. 
B) HDAC4 and HDAC5 are highly homologous, sharing a conserved MEF2 binding 
domain (BD), a nuclear localisation signal (NLS), a deacetylase domain and a 
nuclear export sequence (NES). Phosphorylation by protein kinases at conserved 
serine residues within the N-terminal region is a key determinant of subcellular 
localisation. Oxidation of conserved cysteine residues within the deacetylase 
domain is a phosphorylation-independent post-translational mechanism that can 
also affect HDAC4/5 localisation. Proteolytic cleavage of HDAC4 at a unique site 
results in the generation of an N-terminal fragment that represses MEF2 activity. 
HDAC4 also contains a CaMKII binding domain, which is not present in HDAC5. 
Figure 2: A schematic of the current state of play and avenues for future 
investigation. Class I and class IIa HDACs are now recognized as important and 
opposing regulators of pathological cardiac remodelling, through mechanisms 
that are either dependent on (class I) or independent of (class IIa) histone acetyl 
lysine deacetylase activity. The figure also illustrates various post-translational 
modifications (PTMs) of class IIa HDACs whose role in regulating pathological 
cardiac remodelling is either relatively well established (black) or requires 
further investigation (blue). Potential interactions and cross-regulation between 
different PTMs remain unknown, and recent evidence (Eom et al., 2014) for 
deacetylation of HDAC2 (a class I HDAC) by HDAC5 (a class IIa HDAC) should 
trigger further investigation of regulatory crosstalk between distinct HDAC 
family members.  
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Table 1: HDAC inhibitors attenuate pathological remodelling in experimental models of cardiac injury 
Inhibitor Isoform 
selectivity 
Effect of inhibitor on cardiac phenotype 
Trichostatin A 
(TSA) 
Pan HDACi Blunted cardiac hypertrophy induced by chronic isoprenaline infusion in mice (Kook et al., 2003) 
Blunted cardiac hypertrophy induced by ascending aortic banding in mice and rats (Kee et al., 2006) 
Prevented cardiac hypertrophy induced by chronic angiotensin II infusion in mice (Kee et al., 2006) 
Reversed established cardiac hypertrophy induced by ascending aortic banding in mice (Kee et al., 2006) 
Blunted left ventricular hypertrophy and attenuated cardiac fibrosis induced by transverse aortic banding in mice (Kong et al., 2006) 
Reduced infarct size in mouse models of ischemia/reperfusion injury (Granger et al., 2008; Xie et al., 2014) 
Reduced infarct size and improved functional parameters in Langendorff isolated perfused mouse hearts (Zhang et al., 2010) 
Attenuated pathological remodelling and improved survival in a mouse model of myocardial infarction (Zhang et al., 2012) 
Valproic acid 
(VPA) 
Weak class I 
HDACi  
Blunted cardiac hypertrophy induced by ascending aortic banding in mice (Kee et al., 2006) 
Prevented cardiac hypertrophy induced by chronic angiotensin II infusion in mice (Kee et al., 2006) 
Attenuated left ventricular remodelling and improved systolic function in a rat model of myocardial infarction (Lee et al., 2007) 
Reduced blood pressure and prevented the development of left ventricular hypertrophy and fibrosis in a genetic rat model of 
hypertension (Cardinale et al., 2010) 
Attenuated right ventricular hypertrophy and fibrosis induced by pulmonary artery banding in rats (Cho et al., 2010) 
Attenuated left and right ventricular hypertrophy in a rat model of pulmonary hypertension induced by monocrotaline injection (Cho 
et al., 2010) 
Prevented/reversed cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats (Kee et al., 2013) 
Scriptaid Pan HDACi Blunted left ventricular hypertrophy induced by transverse aortic banding in mice (Kong et al., 2006) 
Reduced infarct size in a mouse model of ischemia/reperfusion injury (Granger et al., 2008) 
SAHA Pan HDACi Reduced blood pressure and attenuated left ventricular hypertrophy and fibrosis in DOCA-salt hypertensive rats (Iyer et al., 2010) 
Reduced infarct size and improved systolic function in a mouse model of ischemia/reperfusion injury (Xie et al., 2014) 
Reduced infarct size and improved systolic function in rabbits when administered prior to ischemia/reperfusion injury or at 
reperfusion (Xie et al., 2014) 
Apicidin Class I HDACi Blunted left ventricular hypertrophy, attenuated cardiac fibrosis and improved systolic function in mice subjected to transverse 
aortic banding (Gallo et al., 2008) 
SK-7041 Class I/pan 
HDACi 
Prevented cardiac hypertrophy induced by ascending aortic banding in mice (Kee et al., 2006) 
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Table 2: Loss- and gain-of-function HDAC mouse models 
Isoform Mouse model Reported cardiac phenotype References 
HDAC1 Global knockout Embryonic lethality between E9.5 and E10.5 due to proliferation 
defects. 
(Lagger et al., 2002) 
 Global knockout Embryonic lethality by E9.5. (Montgomery et al., 2007) 
 Cardiomyocyte-
specific knockout 
No gross cardiac abnormalities basally. Comparable hypertrophic 
response to chronic isoprenaline administration and transverse 
aortic constriction (TAC) as littermate controls. 
(Montgomery et al., 2007) 
 Cardiomyocyte-
specific transgenic 
No evidence of cardiac hypertrophy at 2-3 months of age. (Trivedi et al., 2007) 
HDAC2
 
Global knockout Increased cardiomyocyte hyperplasia during perinatal period. 
Resistant to isoprenaline- and TAC-induced cardiac remodelling. 
Resistant to cardiac hypertrophy induced by transgenic expression 
of the homeobox gene, Hop. 
(Trivedi et al., 2007) 
 Global knockout Neonatal lethality due to ventricular defects. Increased 
cardiomyocyte hyperplasia and apoptosis in P1 hearts. 
Bradycardia. 
(Montgomery et al., 2007) 
 Cardiomyocyte-
specific knockout 
No gross cardiac abnormalities. Comparable hypertrophic 
response to chronic isoprenaline administration as littermate 
controls. 
(Montgomery et al., 2007) 
 Cardiomyocyte-
specific transgenic 
Developed pathological cardiac hypertrophy by 8 weeks of age. 
Further increase in heart mass when crossed with transgenic mice 
overexpressing the homeobox gene, Hop. 
(Trivedi et al., 2007) 
HDAC1/2 Double 
cardiomyocyte-
specific knockout 
Postnatal lethality due to the development of dilated 
cardiomyopathy and cardiac arrhythmias. Phenotype attributed to 
dysregulation of genes encoding ion channels and sarcomeric 
proteins. 
(Montgomery et al., 2007) 
HDAC3 Global knockout Embryonic lethality by E9.5. (Montgomery et al., 2008) 
 Cardiomyocyte-
specific knockout 
Developed significant left ventricular hypertrophy, atrial 
enlargement, interstitial fibrosis and systolic dysfunction by 12 
weeks of age. Phenotype attributed to dysregulation of metabolic 
genes.  
(Montgomery et al., 2008) 
 Cardiomyocyte-
specific transgenic 
Significant thickening of the ventricular walls and diminished lumen 
volume at birth due to increased cardiomyocyte proliferation. 
Normalisation of heart morphology by 2-3 months of age. Similar 
hypertrophic response to chronic isoprenaline treatment as wild-
type littermates. 
(Trivedi et al., 2007; 
Trivedi et al., 2008) 
HDAC4 Global knockout Lethality prior to weaning due to severe growth retardation 
resulting from premature ossification of developing bones. No 
obvious cardiac phenotype. 
(Vega et al., 2004b) 
 Cardiomyocyte-
specific knockout 
Cardiac phenotype has not been extensively described. Normal 
dP/dtmax, dP/dtmin and cardiac output in isolated working hearts. 
Elevated Nppa expression (marker of pathological cardiac 
hypertrophy) compared with wild-type littermates.  
(Hohl et al., 2013) 
HDAC5 Global knockout Developed cardiac hypertrophy by 8 months of age. Displayed 
exaggerated hypertrophic response to TAC and transgenic 
expression of activated calcineurin. Similar hypertrophic response 
to wild-type littermates in response to chronic isoprenaline 
administration.  
(Chang et al., 2004) 
HDAC6
 
Global knockout Protected from developing systolic dysfunction in response to 
chronic angiotensin II infusion or TAC, despite the same degree of 
left ventricular hypertrophy and fibrosis as wild-type littermates.  
(Demos-Davies et al., 
2014) 
HDAC7 Global knockout Embryonic lethality due to cardiovascular defects. (Chang et al., 2006) 
HDAC8 Global knockout Perinatal lethality due to skull defects. No obvious cardiovascular 
abnormalities. 
(Haberland et al., 2009) 
HDAC9 Global knockout Developed cardiac hypertrophy by 8 months of age. Displayed 
exaggerated hypertrophic response to TAC and transgenic 
expression of activated calcineurin. Similar hypertrophic response 
to wild-type littermates in response to chronic isoprenaline 
infusion.  
(Zhang et al., 2002a; 
Chang et al., 2004) 
HDAC5/9 Double global 
knockout 
High incidence of embryonic and perinatal lethality due to 
haemorrhages and ventricular defects. Cardiac hypertrophy was 
observed in the small percentage of double knockout mice that 
survived until adulthood. 
(Chang et al., 2004) 
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